Ipamorelin

Protocol examples

Protocol logic check

Independent evidence

Regulatory status: unapproved or compounded peptide with FDA safety risk flag

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Active cancer or history of malignancy: GH/IGF-1 elevation may promote tumor cell proliferation.
• History of hormone-sensitive malignancies (breast, prostate, colorectal): IGF-1 is a growth factor for these tumor types.
• Active acromegaly or pituitary disorders involving GH excess.
• Diabetic ketoacidosis.
• Diabetes mellitus or significant insulin resistance: GH elevation reduces insulin sensitivity; monitor fasting glucose.
• Concurrent use with GHRP-2 or GHRP-6: receptor competition at GHS-R1a; do not combine two GHRPs.
• Concurrent use with HGH 191aa: additive GH elevation creates redundant axis overstimulation.
• Concomitant glucocorticoid therapy: suppresses pituitary GH response.
• Pregnancy: safety not established.
• Breastfeeding: safety not established.
• Known hypersensitivity to ipamorelin or any formulation excipients.
• Pediatric use in children with closed growth plates.
• Severe cardiac disease or heart failure: GH elevation can increase cardiac workload.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Headache: most commonly reported adverse effect; caused by acute GH pulse-induced vasodilation; typically occurs in the first 1-2 weeks and diminishes with continued use; reported in approximately 20-35% of users in early weeks.
• Mild fatigue or lethargy: transient; within 30-60 minutes post-injection; associated with the GH pulse.
• Dizziness or lightheadedness: approximately 10-15% anecdotally; transient vasodilation; resolves within 30 minutes.
• Injection site irritation: redness, swelling, minor discomfort; reported in approximately 20-30% with subcutaneous injection.
• Mild water retention: GH-mediated sodium and fluid retention; approximately 15% anecdotally; less than CJC-1295 alone; more common in first 2-4 weeks.
• Mild nausea: rare; less than 5% at standard doses; more common at 300mcg+.
• Slight increase in appetite: modest orexigenic effect from GHS-R1a activation; minimal compared to GHRP-6.
• Joint stiffness: GH-mediated periarticular fluid; typically at higher-dose multi-injection protocols.
• Tingling or numbness in hands or feet: paresthesia; less common than with CJC-1295 DAC.
• Vivid dreams: GH elevation during nocturnal sleep cycle.
• Transient mild hypoglycemia: possible when combining with CJC-1295 in a fasted state; GH pulse transiently shifts glucose partitioning.
• Long-term insulin resistance (theoretical, dose and duration dependent): sustained IGF-1 elevation may reduce insulin sensitivity over extended cycles; no direct evidence from ipamorelin-specific studies.

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

Sources

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?pg=3
• PubMed search: Ipamorelin